Bloomberg reports that while antibiotics are essential to many clinical treatments, pharmaceutical producers are growing more reluctant to produce them due in part to declining revenue potential.
Dr. Bill Schaffner, MD, professor of preventive medicine in the Department of Health Policy, explains why recommendations from infectious disease experts to hold new antibiotics in reserves complicates the problem.
Read the full Bloomberg report here: https://www.bloomberg.com/news/articles/2019-05-03/antibiotics-aren-t-profitable-enough-for-big-pharma-to-make-more